On March 27, 2015, the launch meeting of the China Familial Alzheimer’s Disease Research Registry (www.chinacfan.org) and the Cognitive Disorders Clinical Center Registry was held in Beijing Business Hall. Prof. Jia Jianping, the chairman of the conference, shared the report of “Chinese Familial Alzheimer’s Disease Research Program” with all participants; Prof. Li Yong presented the Chinese Familial Alzheimer’s Disease Registry website. Professor Jia Jianping, Chairman of the kick-off meeting, suggested that a population reflecting the homogeneity, concentration, pure pathophysiological changes and course of Alzheimer’s disease (AD) may be the most ideal population to get rid of the dilemma of AD prevention and treatment, and this population is patients with familial Alzheimer’s disease. Prof. Jia Jianping talked about the research goals for familial Alzheimer’s disease (FAD) in China: to establish a platform for FAD research in China, to integrate the power of clinical research and basic research on FAD in China, to establish standards and criteria for FAD research in China; to establish a large clinical database, biomarker and imaging database for familial AD in China; to establish a cohort study of FAD in China, to clarify the genetic mutations that cause The study will establish a Chinese FAD cohort to clarify the disease pattern of FAD caused by genetic mutations and molecular markers for the pre-dementia stage of AD. Prof. Liyong Wu introduced the Chinese Familial Alzheimer’s Disease Registry Network at the kick-off meeting. Familial Alzheimer’s disease refers to two or more consecutive generations in a family with at least two first-degree relatives suffering from Alzheimer’s disease. It is estimated that there are more than 500,000 patients with familial Alzheimer’s disease in China, but the majority of patients and relatives do not receive early diagnosis and professional genetic counseling. The China Familial Alzheimer’s Disease Registry aims to provide a platform for professional consultation and patient registration for patients and families with familial Alzheimer’s disease, and to provide a platform for research and cooperation for researchers with familial Alzheimer’s disease to promote the progress of Alzheimer’s disease research in China. The conference laid a solid foundation for China to integrate clinical resources, concentrate on research, and conduct more in-depth research on the pathogenesis and early prevention of Alzheimer’s disease. The Chinese Familial Alzheimer’s Disease Registry Network is located at www.chinacfan.org.